Physician profile

Erin E Neff

Psychiatric/Mental Health (Nurse Practitioner) · Belpre, OH

NPI 1912218983

$766.79

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$157.42

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $432.76 2021-2024
Axsome Therapeutics, INC. $125.00 2024 Auvelity
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $58.84 2021-2022
Neurocrine Biosciences, INC. $37.57 2022
Otsuka America Pharmaceutical, INC. $32.45 2021-2022
Corium, LLC $18.46 2023 Azstarys
Alkermes, INC. $17.96 2021
Avanir Pharmaceuticals, INC. $16.60 2022
Takeda Pharmaceuticals U.S.A., INC. $14.35 2021
Lundbeck LLC $12.80 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Erin E Neff

$766.79

in general payments reported 2019-2025

Years
2021-2024
Top company
Abbvie INC.

https://glasscript.com/doctor/10438615/erin-e-neff

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.